Skip to main content
AVCRF
OTC Life Sciences

Avricore Health Reports Steep Revenue Decline and Going Concern Warning Amid Major Customer Loss

Analysis by Wiseek.ai
Sentiment info
Negative
Importance info
9
Price
$0.035
Mkt Cap
$3.57M
52W Low
$0.013
52W High
$0.254
Market data snapshot near publication time

summarizeSummary

Avricore Health Inc. reported a substantial decline in revenue and a significant comprehensive loss for the nine months ended September 30, 2025, leading to a material uncertainty regarding its ability to continue as a going concern following the expiration of its agreement with a major customer.


check_boxKey Events

  • Going Concern Warning Issued

    Management disclosed a material uncertainty regarding the company's ability to continue as a going concern, citing historical operating losses and negative cash flows.

  • Significant Revenue Decline

    Revenue for the nine months ended September 30, 2025, plummeted 85% year-over-year to $500,433, primarily due to the expiration of a major customer agreement.

  • Shift to Comprehensive Loss

    The company reported a comprehensive loss of $916,042 for the nine-month period, a significant reversal from income in the prior year.

  • Cash Flow Deterioration

    Net cash used in operating activities resulted in a $600,111 decrease in cash and cash equivalents for the nine-month period.


auto_awesomeAnalysis

The company's financial results for the nine months ended September 30, 2025, show a drastic 85% year-over-year revenue decrease and a shift to a comprehensive loss of $916,042. This severe deterioration is primarily due to the conclusion of its agreement with Shoppers Drug Mart, a major customer. Management explicitly stated a "material uncertainty" about the company's ability to continue as a going concern, highlighting its historical operating losses and negative cash flows. While the company outlines a strategy to focus on the UK market and redeploy existing devices, the immediate financial challenges and the going concern warning present significant risks to investors.

At the time of this filing, AVCRF was trading at $0.04 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.6M. The 52-week trading range was $0.01 to $0.25. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed AVCRF - Latest Insights

AVCRF
Feb 17, 2026, 6:15 AM EST
Filing Type: 6-K
Importance Score:
8
AVCRF
Jan 12, 2026, 3:09 PM EST
Filing Type: 6-K
Importance Score:
9